Search company, investor...
Asuragen company logo

Asuragen

asuragen.com

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$88.34M

Valuation

$0000 

About Asuragen

Asuragen is a fully integrated molecular diagnostics company focused on oncology and companion diagnostics with special capabilities in the areas of mRNA and miRNA. Based in Austin, Texas, the company has strong R&D, regulatory, cGMP manufacturing, and global commercial capabilities to support a broad range of molecular diagnostic products providing rapid identification of genetic abnormalities associated with oncology and genetic diseases.On March 3rd, 2021, Asuragen was acquired by Bio-Techne at a valuation between $215M and $320M.

Headquarters Location

2150 Woodward Street Suite 100

Austin, Texas, 78744,

United States

512-681-5200

Missing: Asuragen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Asuragen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Asuragen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Asuragen is included in 7 Expert Collections, including Medical Devices.

M

Medical Devices

11,865 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

Asuragen Patents

Asuragen has filed 1 patent.

The 3 most popular patent topics include:

  • DNA
  • Genetics
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/16/2018

2/1/2022

Molecular biology, DNA, Biotechnology, RNA, Genetics

Grant

Application Date

1/16/2018

Grant Date

2/1/2022

Title

Related Topics

Molecular biology, DNA, Biotechnology, RNA, Genetics

Status

Grant

Latest Asuragen News

07:00 EDT Asuragen to Showcase Innovative Diagnostic Lab Solutions at AMP 2022 Conference

Oct 31, 2022

News provided by Share this article Company also launches new Armored DNA™ molecular controls for monkeypox and closely related viruses MINNEAPOLIS, Oct. 31, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming annual meeting of the Association for Molecular Pathology (AMP), taking place November 1-5 in Phoenix, Ariz. The company also announced the commercial availability of new molecular controls for monkeypox and other non-variola Orthopoxvirus DNA viruses. At AMP, Asuragen will host two educational workshops, one focused on a streamlined workflow and equitable testing approach for genetic testing and the other on rapid development of molecular controls for emerging diseases. Scientists from the company will also present several posters with updates about clinical tests based on nanopore sequencing technology, molecular controls for SARS-CoV-2 testing, and more. Educational Workshops November 2, 12pm-12:50pm, Room 223 Presenters: Barbara Anderson, Duke University Health System; Gary Latham, Asuragen In this workshop, a clinical lab expert will talk about her experience implementing a new targeted CFTR testing kit that provides more equitable coverage of people of diverse ancestry, a workflow that is fast and easy to run, and a protocol that can be combined with other commonly tested carrier screening genes using a single analysis instrument. Molecular Controls for Emerging Diseases: The Need for Rapid Development and Harmonization November 2, 1pm-1:50pm, Room 223 Presenters: Erica Frew, Asuragen; Deepa Eveleigh, Asuragen This educational session will update attendees on recent efforts to expedite development of molecular controls to enable reliable and rigorous testing of emerging diseases, such as for SARS-CoV-2 and monkeypox. Poster Presentations Presenter: Jonathan Turner Reverse Transcription Cycling Achieves Greater than 100% cDNA Conversion with Implications for Ultra-High Sensitivity of Clinically-Actionable, Oncogenic RNA Mutations Presenter: Melissa Church A Streamlined PCR/Nanopore Sequencing Carrier Screening Panel for Cystic Fibrosis, Spinal Muscular Atrophy, and Fragile X Syndrome Presenter: Jon Kemppainen Presenter: Sikander Gill In addition to its AMP activities, Asuragen also released new Armored DNA™ (RUO) synthetic controls for monkeypox and other non-variola Orthopoxvirus DNA viruses that can be used as positive controls for clinical testing and assay development. Armored products encapsulate DNA in a protein coating to prevent degradation and ensure stability of the control even during harsh analysis processes. These molecular controls were designed based on DNA sequence guidance published by the U.S. Centers for Disease Control and Prevention and harmonized to a reference standard from the National Institute of Standards and Technology. "With the emergence of the latest monkeypox outbreak, patient access to clinical laboratory testing has been severely limited, hindering our ability to respond quickly and effectively to this public health threat," said Kim Kelderman, President of Bio-Techne's Diagnostics and Genomics segment. "We are pleased to release high-quality molecular controls using our proven Armored DNA technology. We believe this will help more labs ramp up testing for monkeypox and related viruses with a non-infectious control for safe operations." About Asuragen, a Bio-Techne Brand Asuragen provides best-in-class molecular diagnostic products to improve the way patients are treated in genetics and oncology. Our diagnostic systems, which include proprietary chemistry and software, are designed for use with widely available instruments to ease adoption and quickly expand lab test menus. Our diagnostic tests and companion diagnostic partnerships address current and emerging clinical needs in reproductive health, cancer diagnosis and monitoring and inherited disease. Asuragen also offers a suite of unique, target-specific molecular controls that have been used in IVD assays for more than 20 years to ensure optimal performance. For more information, visit  www.asuragen.com .

Asuragen Frequently Asked Questions (FAQ)

  • When was Asuragen founded?

    Asuragen was founded in 2006.

  • Where is Asuragen's headquarters?

    Asuragen's headquarters is located at 2150 Woodward Street, Austin.

  • What is Asuragen's latest funding round?

    Asuragen's latest funding round is Acquired.

  • How much did Asuragen raise?

    Asuragen raised a total of $88.34M.

  • Who are the investors of Asuragen?

    Investors of Asuragen include Bio-Techne, Paycheck Protection Program, PTV Sciences, Golden Gate Capital, Growth Capital Partners and 9 more.

  • Who are Asuragen's competitors?

    Competitors of Asuragen include Kereos, Viridian Therapeutics, Spinifex, Marval Biosciences, Amorcyte and 13 more.

Compare Asuragen to Competitors

D
Delphic Diagnostics

Delphic aims to provide a full suite of HIV diagnostics, from simple viral load testing through to advanced genetic tests, to pharmaceutical organisations and clinicians. Some of Delphic's tests are and have been developed internally. As part of MMC's investment, the University of Liverpool's Therapeutic Drug Monitoring service, was "˜spun in' to the business.

V
Valens Therapeutics

Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics

S
Supercritical Fluid Technologies

Supercritical Fluid Technologies develops solutions for demanding separation and material processing needs. SFT provides equipment and custom solutions to meet specific needs in supercritical fluid extraction, reaction chemistry and high pressure applications.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

A
ALEXIS Biochemicals

ALEXIS Biochemicals is an internationally recognized brand acknowldeged as engaged in producing and commercializing high quality reagents in key research areas and an established source for a panel of products to scientific experts in the field.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.